Inactive Instrument

Press Releases Hemispherx BioPharma, Inc Nyse

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 10	AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	CI
Apr. 02	Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Apr. 25	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Apr. 18	GL
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	Apr. 15	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Apr. 11	GL
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	Apr. 10	GL
Challenges To Advance Notice Bylaws Are Spiking	Apr. 08	AQ
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Apr. 02	GL
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference	Mar. 28	GL
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	Mar. 26	GL
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	Mar. 26	AQ
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Mar. 25	AQ
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	Mar. 25	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Mar. 22	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Mar. 20	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Mar. 20	AQ
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity	Mar. 15	GL
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity	Mar. 15	AQ
AIM ImmunoTech Announces Launch of CEO Corner Platform	Mar. 07	GL
AIM ImmunoTech Announces Launch of CEO Corner Platform	Mar. 07	AQ
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update	Feb. 29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Hemispherx BioPharma, Inc Nyse

Equities

Press Releases

Filters